Evidence map›Paper›PMID 30420258›Full record

ArticleJournal of pediatric urology2019

Elevated urinary lipocalin-2, interleukin-6 and monocyte chemoattractant protein-1 levels in children with congenital ureteropelvic junction obstruction.

L Yu, L Zhou, Q Li, S Li, X Luo, C Zhang, B Wu, J D Brooks, H Sun

Open access · greenAbstract read
In one paragraph

Article in Journal of pediatric urology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. The use of biomarkers in the diagnosis and treatment of obstruction of the upper urinary tract in children.Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia · 2022
    Review
  4. American journal of physiology. Renal physiology · 2020
    Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

L YuXinjiang Institute of Pediatrics, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China.
L ZhouDepartment of Pediatric Surgery, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China.
Q LiXinjiang Institute of Pediatrics, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China.
S LiDepartment of Pediatric Surgery, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China.
X LuoXinjiang Institute of Pediatrics, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China.
C ZhangDepartment of Urology, Stanford University School of Medicine, Stanford, CA, USA.
B WuDepartment of Urology, Stanford University School of Medicine, Stanford, CA, USA.
J D BrooksDepartment of Urology, Stanford University School of Medicine, Stanford, CA, USA. Electronic address: jdbrooks@stanford.edu.
H SunXinjiang Institute of Pediatrics, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China. Electronic address: hesun@xjrmyy.com.
People's Hospital of Xinjiang Uygur Autonomous Region · CNStanford University · USStanford Medicine · US

Funding

RNA markers of renal damage due to obstructionR01DK101736 · NIDDK · STANFORD UNIVERSITY · PI BROOKS, JAMES D. · 2015 to 2017
$712k
NIDDK NIH HHS R01 DK101736
6 · The paper itself

Abstract

introductionIn children with congenital ureteropelvic junction obstruction (UPJO), urinary biomarkers could assist in the diagnosis of renal damage or kidneys at risk for damage. Urinary levels of interleukin-6 (IL6), neutrophil gelatinase-associated lipocalin (LCN2), monocyte chemoattractant protein-1 (MCP1), and transforming growth factor-β1 (TGFB1) proteins have been correlated with renal damage in several contexts. Whether they might be useful non-invasive biomarkers of obstructive nephropathy due to unilateral and bilateral congenital UPJO was tested. PATIENTS AND

methodsA cohort study was performed at People's Hospital of Xinjiang Uygur Autonomous Region in China. Bladder urine samples from 17 patients with UPJO were obtained before surgical intervention and from 17 healthy age-matched controls. Levels of IL6, LCN2, MCP1, and TGFB1 were determined by enzyme-linked immunosorbent assay and normalized to urinary creatinine levels.

resultsLevels of urinary LCN2, MCP1, and IL6 were significantly elevated in the urine from individuals with UPJO compared with controls (P = 0.0003, P = 0.0003, and P = 0.0073, respectively). Children with bilateral UPJO (n = 5) showed significantly higher levels of IL6, LCN2, and MCP1 protein in their urine compared with controls or those with unilateral UPJO (n = 12; P = 0.007, P < 0.0001, and P = 0.0002, respectively). Combining LCN2 and MCP1 slightly improved biomarker performance. DISCUSSION: Urinary biomarkers could be used in obstructed patients to monitor for renal damage and might find particular utility on patients with bilateral UPJO. Monitoring urinary biomarkers and imaging features in untreated patients could provide insights into the natural history of renal damage due to obstruction and will be necessary to test their performance characteristics as biomarkers.

conclusionsUrinary levels of LCN2 and MCP1 protein are promising biomarkers monitoring children with UPJO, particularly in those with bilateral disease.

Indexed as

Kidney PelvisAdolescentBiomarkersChemokine CCL2ChildChild, PreschoolCohort StudiesFemaleHumansInfantInterleukin-6Lipocalin-2MaleTransforming Growth Factor beta1Ureteral ObstructionBiomarkersChemokine CCL2Interleukin-6LCN2 protein, humanLipocalin-2TGFB1 protein, humanTransforming Growth Factor beta1LCN2MCP1Renal damageUPJOUrinary biomarker

Identifiers

PMID30420258
PMCPMC6401238
OpenAlexW2897249906

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.